Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Increases Purchase Price for Nanosphere

NEW YORK (GenomeWeb) – Luminex announced today that it has raised the purchase price for Nanosphere to $1.70 per share in cash from the $1.35-per-share price it originally offered for the molecular diagnostics developer.

This raises the share-price value of the transaction to approximately $77 million from $58 million.

Molecular diagnostics and life sciences research tools firm Luminex first announced its purchase agreement with Nanosphere in mid-May. At that time, the company also said it would pay or help Nanosphere pay $25 million in debt outstanding as of March 31. The deal was expected to close on or before July 1.

The increase came in response to an unsolicited bid from an unnamed third party, Luminex said. That company offered to buy Nanosphere for $1.50 per share.

Nanosphere's shares have climbed 27 percent to $1.67 in morning trading on the Nasdaq. Luminex's shares are up nearly 2 percent to $20.19.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.